Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.

CONCLUSIONS: Our data suggest that the RTX is a promising alternative to Ponticelli's regimen even at low-doses. This makes RTX a cost-effective treatment of primary MN in the short and medium terms.
PMID: 32594370 [PubMed - as supplied by publisher]

Source: Journal of Nephrology - June 26, 2020 Category: Urology & Nephrology Authors: Fenoglio R, Baldovino S, Sciascia S, De Simone E, Del Vecchio G, Ferro M, Quattrocchio G, Naretto C, Roccatello D Tags: J Nephrol Source Type: research